Lipid–Polymer Hybrid Nanosystems: A Rational Fusion for Advanced Therapeutic Delivery

Shweta Jain, Mudit Kumar, Pushpendra Kumar, Jyoti Verma, Jessica M. Rosenholm, Kuldeep K. Bansal, Ankur Vaidya

Research output: Contribution to journalReview Article or Literature Reviewpeer-review

6 Citations (Scopus)
46 Downloads (Pure)


Lipid nanoparticles (LNPs) are spherical vesicles composed of ionizable lipids that are neutral at physiological pH. Despite their benefits, unmodified LNP drug delivery systems have substantial drawbacks, including a lack of targeted selectivity, a short blood circulation period, and in vivo instability. lipid–polymer hybrid nanoparticles (LPHNPs) are the next generation of nanoparticles, having the combined benefits of polymeric nanoparticles and liposomes. LPHNPs are being prepared from both natural and synthetic polymers with various techniques, including one- or two-step methods, emulsification solvent evaporation (ESE) method, and the nanoprecipitation method. Varieties of LPHNPs, including monolithic hybrid nanoparticles, core–shell nanoparticles, hollow core–shell nanoparticles, biomimetic lipid–polymer hybrid nanoparticles, and polymer-caged liposomes, have been investigated for various drug delivery applications. However, core–shell nanoparticles having a polymeric core surrounded by a highly biocompatible lipid shell are the most commonly explored LPHNPs for the treatment of various diseases. In this review, we will shed light on the composition, methods of preparation, classification, surface functionalization, release mechanism, advantages and disadvantages, patents, and clinical trials of LPHNPs, with an emphasis on core–shell-structured LPHNPs.
Original languageEnglish
Article number437
JournalJournal of Functional Biomaterials
Issue number9
Publication statusPublished - 23 Aug 2023
MoE publication typeA2 Review article in a scientific journal


  • Nanoparticles
  • Cancer
  • Drug delivery


Dive into the research topics of 'Lipid–Polymer Hybrid Nanosystems: A Rational Fusion for Advanced Therapeutic Delivery'. Together they form a unique fingerprint.

Cite this